Content sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. The diagnosis of interstitial lung disease (ILD) brings a unique burden to patients. A broad category of more than 200 rare and potentially serious lung diseases — including idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and chronic fibrosing ILD with a progressive phenotype — some…